リウマチ病セミナー　XVII　2006

出版社： 永井書店
著者：
発行日： 2006-12-16
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 4815917744
シリーズ： リウマチ病セミナー
電子書籍版： 2006-12-16 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,020 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,510 円(税込)

購入する

商品紹介

本セミナーは、1990年以来毎年発行されて、今回で１７冊目となり、常に本領域の水先案内人として、最新の研究成果・治療データを提供してきた。多彩で日進月歩の進展をみせるリウマチ学を一流の研究者たちが思う存分成果を披露している。高安病やAAアミロイドーシスに対するIL-6の効果、OAの遺伝子アスポリン、アディポサイトカイン、Toll-like receptor、PGD2、リウマチ病とspirituality、PTSＤ、RAに対する薬物療法、悪性リンパ腫などをとりあげた。

目次

  • リウマチ病セミナー　XVII　2006

    ―目次―

    炎症リウマチ
    骨関節、脊椎、神経
    評価
    検査法
    生物学的反応
    治療と副作用
    手術

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.12 掲載の参考文献
1) Balkwill F, Mantovani A. Inflammation and cancer:back to Virchow? Lancet 2001;357(9255) :539-545.
PubMed
2) Magrath I. Molecular basis of lymphomagenesis. Cancer Res 1992;52(19 Suppl) :5529s-5540s.
 
3) 吉野正.リンパ組織の形態と機能.1血液・腫瘍科2004;49(Suppl 4) :19-25.
 
4) Zintzaras E, Voulgarelis M, Moutsopoulos HM, et al. The risk of lymphoma development in autoimmune diseases:a meta-analysis. Arch Intern Med 2005;165(20) :2337-2344.
PubMed
5) Kojima M, Nakamura S, Futamura N, et al. Malignant lymphoma in patients with rheumatic diseases other than Sjogren's syndrome:a clinicopathologic study of five cases and a review of the Japanese literature. Jpn J Clin Oncol 1997;27(2) :84-90.
 
6) Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89(6) :888-892.
PubMed
7) 菅井 進.Sjogren症候群とリンパ増殖性疾患.日内会誌2000;89:1948-1956.
 
8) Isaacson P, Wright DH, et al. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984;53(11) :2515-2524.
PubMed
9) Sweeney DM, Manzi S, Janosky J, et al. Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 1995;1478-1482.
PubMed
10) Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52(5) :1481-1490.
PubMed
11) Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40(4) :761-768.
PubMed
12) Weyand CM, Goronzy JJ, Kurtin PJ, et al. Lymphoma in rheumatoid arthritis:an immune system set up for failure. Arthritis Rheum 2006;54(3) :685-689.
PubMed
13) Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48(4) :963-970.
PubMed
14) Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis:nested case-control study. BMJ 1998;18;317(7152) :180-181.
 
15) Baecklund E, Sundstrom C, Ekbom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis:increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48(6) :1543-1550.
PubMed
16) Kamel OW, van de Rijn M, Weiss LM, et al. Brief report:reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993 ;328:1317-1321.
PubMed
17) Kamel OW, Weiss LM, van de Rijn M, et al. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996;20(10) :1279-1287.
PubMed
18) Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14(6) :1943-1949.
PubMed
19) Georgescu L, Quinn GC, Schwartzman S, et al. Lymphoma in patients with rheumatoid arthritis:association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26(6) :794-804.
PubMed
20) Tosato G, Steinberg AD, Blaese RM, et al. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med 1981;305(21) :1238-1243.
PubMed
21) Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-311.
PubMed
22) Sibilia J, Liote F, Mariette X, et al. Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed 1998;65(4) :267-273.
PubMed
23) Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate:a 3-year prospective study in France. Blood 2002;99(11) :3909-3915.
PubMed
24) Moder KG, Tefferi A, Cohen MD, et al. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis:aretrospective study. Am J Med 1995;99(3) -276281.
 
25) Stern RS, Zierler S, Parrish JA, et al. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 1982;50(5) :869-872.
PubMed
26) Bailin PL, Tindall Jp, Roenigk HH Jr, et al. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA 1975;232(4) :359-362.
PubMed
27) Matsuo K, Suzuki R, Hamajima N, et al. Association between polymorphisms of folate-and methioninemetabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97(10) :3205-3209.
PubMed
28) Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis:the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50(6) :1740-1751.
PubMed
29) Bongartz T, Sutton N, Sweeting MJ, et al, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies:systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19) :2275-2285.
 
30) Geborek P, Bladstrom A, Turesson C, et al, Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64(5) :699-703.
 
31) Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis:lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64(10) :1414-1420.
PubMed
32) Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;17:343(7) :481-492.
 
33) Alspaugh MA, Henle G, Lennette ET, et al. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J Clin Invest 1981;67(4) :1134-1140.
PubMed
34) Toussirot E, Auger I, Roudier C, et al. HLA-DR polymorphism influences T-cell precursor frequencies to Epstein-Barr virus(EBV) gp 110:implications for the association of HLA-DR antigens with rheumatoid arthritis. Tissue Antigens 1999;54(2) :146-152.
 
35) Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54(3) :692-701.
 
P.21 掲載の参考文献
1) Takayasu M. A case with peculiar changes of the retinal central vessels. Acta Soc Ophthalmol Jpn 1908;12:554-555.
 
2) Numano F. Differences in clinical presentation and outcome in different countries for Takayasu's arteritis. Curr Opin Rheumatol 1997;9:12-15.
PubMed
3) 塩沢俊一.高安動脈炎.膠原病学2005,p 396-399,東京,丸善.
 
4) Numano F, Kobayashi Y, Maruyama Y, et al. Takayasu arteritis:clinical characteristics and the role of genetic factors in its pathogenesis. Vasc Med 1996;1:227-233.
PubMed
5) Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu Arteritis. Arthritis Rheum 2004;50:2296-2304.
PubMed
6) Noris M, Daina E, Gamba S, et al. Interleukin-6 and RANTES in Takayasu arteritis:aguide for therapeutic decision? Circulation 1999;100:55-60.
 
P.35 掲載の参考文献
1) Felty AR. Chronic arthritis in the adult, associated with splenomegaly and leucopenia:a report of five cases of an unusual clinical syndrome. Johns Hopkins Hospital Bulletin 1924;395:16.
 
2) Hanrahan EM Jr, Miller SR. Effect of splenectomy in Feltyis syndrome. JAMA 1932;99:1247.
 
3) Termini TE, Biundo JJ, Ziff M. The rarity of the Felty's syndrome in blacks. Arthritis Rheum 1979;22:999.
PubMed
4) Balint GP, Balint PV. Felty's syndrome. Best Practice&Best Research Clinical Rheumatology 2004;18:631.
 
5) 井上哲文.Felty症候群.臨床医26(増刊号) 2000;1444.
 
6) 永沢逸人,竹内 勤.Felty症候群.日本臨床63(増刊5号) 2005;281.
 
7) 織部元廣,酒井敏夫,溝辺 薫ほか.慢性関節リウマチにおける脾臓の大きさ-腹部Echoによる検討-. 九州リウマチ1984;3:176.
 
8) 辻本達寛,鶴園卓也,松村吉庸.関節リウマチにおける脾腫の検討.大阪医学2005;39:28.
 
9) 坂根 剛,土田登美子.フェルティ症候群.現代医療1989;21:1354.
 
10) 鈴木康夫,田中千絵,尾崎承一ほか.メトトレキサート(MTX)により誘発されるリンパ増殖性疾患.リウマチ科2002;28:498.
 
11) Friman C, Schlant J, Davis P. HLA-DR 4 in Felty's syndrome. J Rheumatol 1985;12:628.
 
12) Wiik A, Munthe E. Complement-fpting granulocyte-specific antinuclear factors in neutropenic cases of rheumatoid arthritis. Immunology 1974;26:1127.
PubMed
13) Starkebaum G, Singer JW, Arend WP. Humoral and cellular immune mechanism of neutropenia in Felty's syndrome. Clin Exp Immunol 1980;39:307.
PubMed
14) Hellmich B, Csernok E, Schatz H, et al:Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 2002;46:2384.
PubMed
15) 小川啓恭.Pseudo-Felty's syndrome.リウマチ病セミナーII(七川歡次監修) ,1991, p 11-16,永井書店, 大阪.
 
16) 井上啓司,加藤周司,計良夏哉ほか.G-CSFとステロイドの併用が白血球減少症に対して有効であったFelty症候群の1例.診断と臨床1994;82:2000.
 
17) Allen LS, Groff G. Treatment of Felty's syndrome with low dose oral methotrexate. Arthritis Rheum 1986;29:902.
PubMed
18) Talip F, Walker N, Khan W, et al. Treatment of Felty's syndrome with leflunomide. J Rheumatol 2001;28:868.
 
19) Ishikawa K, Tsukada Y, Tamura S, et al. Salazosulfapyridine-induced remission of Felty's syndrome along with significant reduction in neutrophil-bound immunoglobulin G. J Rheumatol 2003;30:404.
PubMed
20) Ravindran J, Shenker A, Bhalla K, et al. Case report:response in proteinuria due to AA amyloidosis but not to Felt's syndrome in a patient with rheumatoid arthritis treated with TNF-α blockade. Rheumatology 2004;43:669.
 
21) Ghavami A Genevay S, Fulpius T, et al. Etanercept in treatment of Felt's syndrome. Ann Rheum Dis 2005;64:1090.
 
22) Sordet C, Gottenberg J-E, Hellmich B, et al. Lack of efficacy of rituximab in Felty's syndrome. Ann Rhem Dis 2005 ;65:332.
 
23) 古川幸夫.田中文夫,望月康弘.Felty症候群に摘脾を施行した1例.公立能登総合病院医学雑誌2001;12:24.
 
24) Tujimoto T, Kawano K, Taniguchi M, et al. Nodular regenerative hyperplasia, peliosis hepatitis and plexiform angiopathy of the liver;association of Felt's syndrome, chronic tyroiditis(Hashimoto's disease) and chronic sialoadenitis.大労医誌1997;21:51.
 
25) 鹿毛政義.門脈圧亢進症をきたす疾患の肝生検診断.病理と臨床2005;23:281.
 
26) 日高 央,國分茂博.特発性門脈圧亢進症の診断基準.病型分類・重症度.内科2005;95:1170.
 
27) Blendis LM, Parkinson MC, Shilkill KB, et al. Nodular regenerative hyperplasia of the liver in Felty's syndrome. Quarterly journal of medicine 1974;43:25.
 
P.44 掲載の参考文献
1) Shiozawa S, Kuroki Y, Kim M, et al. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992;35:417-422.
PubMed
2) 塩沢俊一,塩沢和子.SLEの精神神経症状.総合臨床1994;43:1140-1145,
 
3) ACR Ad Hoc Committee. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
 
4) Johnson RTF, Richardson EP. The neurological manifestations of systemic lupus erythematosus. A clinical-pathological study of 24 cases and review of the literature. Medicine 1968;47:337-369.
 
5) Van Dam AP. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 1991;11:1-11.
PubMed
6) Shiozawa S, Chihara K, Shiozawa K, et al. A sensitive radioimmunoassay for alpha-interferon:circulating α -interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients. Clin Exp Immunol 1986;66:77-87.
 
7) Shiozawa S, Yoshikawa N, Iijima K, et al. A sensitive radioimlnunoassay for circulating α -interferon in the plasma of healthy children and patients with measles virus infection, Clin Exp Immunol 1988;73:366369.
 
8) Shiozawa S, Tanaka Y, Morimoto I, et al. Radioimmunoassay of circulating alpha-interferon with reference to aging and osteoporosis. Gerontology 1989;35:305-310.
PubMed
9) Shiozawa S, Shiozawa K, Shimizu S, et al. Immunoreactive circulating alpha-interferon is low in Sj?gren's yndrome. Br J Rheumatol(Rheumatology) 1990;29:50-52.
 
10) Shiozawa S, Shiozawa K, Kita M, et al. A preliminary study on the effect of alpha-interferon treatment on the joint inflammation and serum calcium in rheumatoid arthritis. Br J Rheumatol(Rheumatology) 1992;31:405-408.
 
11) Shiozawa S, Morimoto I, Tanaka Y, et al. A preliminary study on the interferon- α treatment for xerostomia of Sjogren's syndrome. Br J Rheumatol(Rheumatology) 1993;32:52-54.
 
12) Saigo K, Shiozawa S, Shiozawa K, et al. Alpha-interferon treatment for adult T cell leukemia:low levels of circulating alpha-interferon and its clinical effectiveness. Blut 1988;56:83-86.
PubMed
13) Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFNa for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998;18:255-262.
 
14) Preble OT, Black RI, Friedman RM, et al. Systemic lupus erythematosus:presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982;216:429-431.
 
15) Yutterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401-406.
 
16) Yee Am, Yip YK, Fischer HD, et al. Serum activity that confers acid lability to alpha-interferon in systemic lupus erythematosus:its association with disease activity and its independence from circulating alpha-interferon. Arthritis Rheum 1990;33:563-568.
PubMed
17) Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythe-matosus blood. J Exp Med 2003;197:711-723.
 
18) Von Wussow P, Jakschies D, Hochkeppel H, et al. MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:914-918.
PubMed
19) Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-2615.
PubMed
20) Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE, Autoimmunity 2003;36:481-490.
PubMed
21) Han GM, Chen SL, Shen N, et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes lmmun 2003;4:177-186.
 
22) Ye S, Pang H, Gu YY, et al. Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1. Rheumatology(Oxford) 2003;42:1155-1163.
PubMed
23) Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-3967.
PubMed
24) Sigurdsson S, Nordmark G, Goring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005;76:528-537.
PubMed
25) Bengtsson AA, Sturfelt G, Truedsson L, et al Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-671.
PubMed
26) Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systelnic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-1503.
PubMed
27) Ronnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991;30:537-540.
PubMed
28) Tolayrnat A, Leventhal B, Sakarcan A, et al:Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 1992;120:429-432.
 
29) Morris LF, Lemak NA, Arnett Jr, et al. Systemic lupus erythematosus diagnosed during interferon alfa therapy.South Med J 1996;89:810-814.
 
30) Batteux F, Palmer P, Daeron M, et al. FCgammar II(CD 32) -dependent induction of interferon-alpha by serum from patients with lupus erythematosus. Eur Cytokine Netw 1999;10:509-514.
 
31) Bave U, Magnusson M, Eloranta ML, et al. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003;171:3296-3302.
PubMed
32) Vallin H, Perers A, Alm GV, et al. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999; 163:6306-6313.
PubMed
33) Lovgren T, Eloranta ML, Bave U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50:1861-1872.
PubMed
34) Barrat F, Meeker T, gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-1139.
PubMed
35) Loza-Tulimowska M, Semkow R, Michalak T, et al. Autoantibodies in sera of influenza patients. Acta Virol 1976;20:202-207.
PubMed
36) Niwa Y, Sakane T, Kanoh T, et al. Transient autoantibodies with elevated complement levels in common viral diseases. J Clin Lab Immunol 1984;13:183-188.
PubMed
37) unziker L, Recher M, Macpherson AJ, et al. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat Immunol 2003;4:343-349.
 
38) Kato H, Takeuchi O, Sato S, et al. Differential roles of DMA 5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101-105.
 
39) Cederblad B, Alm GV. Infrequent but efficient interferon-alpha-producing human mononuclear leukocytes induced by herpes simplex virus in vitro studied by immuno-plaque and limiting dilution assays. J Interferon Cytokine Res 1990;10:65-73.
 
40) Cederblad B, Blomberg S, Vallin H, et al. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 1998;11:465-470.
 
41) Blanco P, Palucka AK, Gill M, et al.Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-1543.
PubMed
42) Gill MA, Blanco P, Arce E, et al.Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum Immunol 2002;63:1172-1180.
PubMed
43) Blomberg S, Eloranta ML, Cederblad B, et al. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001;10:484-490.
PubMed
44) Ronnblom L, Alm GV. The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum Immunol 2002;63:1181-1193.
PubMed
P.51 掲載の参考文献
1) Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System(VAERS) database.Clin Exp Rheumatol 2002 ;20:767-771.
PubMed
2) Geier DA, Geier MR. Rubella vaccine and arthritic adverse reactions:An analysis of the Vaccine Adverse Events Reporting System(VAERS) database from 1991 through 1998. Clin Exp Rheumatol 2001;19:724-726.
 
3) Lathrop SL, Ball R, Haber P, et al. Adverse event reports following vaccination for Lyme disease:December 1998-July 2000. Vaccine 2002;20:1603-1608.
PubMed
4) Ferrazzi V, Jorgensen C, Sany J. Inflammatory joint disease after immunizations. A report of two cases. Rev Rhum Eng Ed 1997;64:227-232.
 
5) Vial T and Descotes J. Autoimmune diseases and vaccinations. Eur J Dermatol 2004;14:86-90.
PubMed
6) Glaser R, Robles TF, Sheridan J, et al. Mild depressive symptoms are associated with a amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry 2003; 60:1009-1014.
PubMed
7) Iyngkaran P, Limaye V, Hill C, et al. Rheumatoid vasculitis following influenza vaccination. Rheumatology (Oxford) 2003;42:907-909.
PubMed
8) Kaul A, Adler M, Alokaily F, et al. Recurrence of reactive arthritis after a booster dose of tetanus toxoid. Ann Rheum Dis 2002;61:185.
PubMed
9) Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'Vaccinosis':A dangerous liaison? J Autoimmun 2000;14:1-10.
PubMed
10) Arshi S, Sadeghi-Bazargani H, Ojaghi H, et al. The first rapid onset optic neuritis after measles-rubella vaccination:case report. Vaccine 2004;22:3240-3242.
PubMed
11) Marti J, Anton E. Polymyalgia rheumatica complocating influenza vaccination. J Am Geriatr Soc 52:1412.
PubMed
12) Hogarth MB, Thomas S, Seifert MH, et al. Reiteris syndrome following intravesical BCG immunotherapy.Postgrad Med J 2000;76:791-793.
 
13) Shoenfeld Y, Aron-Maor A, Tanai A, et al. BCG and autoimmunity:Another two-edged sword. J autoimmun 2001 ;16:235-240.
 
14) Mouly S, Berenbaum F, Kaplan G. Remitting seronegative symmetrical synovitis with pitting edema following intravesica bacillus Calmette-Guerin instillation. J Rheumatol 2001;28:1699-1701.
 
15) Pardalidis NP, Papatsoris AG, Kosmaoglou, et al. Two cases of acute polyarthritis secondary to intravesical BCG adjuvant therapy for superficial bladder cancer. Clin Rheumatol 2002;21:536-537.
PubMed
16) Orikasa K, Namima T, Ota S, et al, Acute eosinophilic pneumonia associated with intravesical bacillus Calmette-Guerin therapy of carcinoma in situ of the bladder. Internat J Urolo 2003;10:622-624.
 
17) Narvaez J, Castro-Bohorquez, Vilaseca-Momplet J, et al. Sjogren's-like syndrome following intravesical bacillus Calmette-Guerin immunotherapy. Am J Med 2003;115:418-420.
 
18) Lamm DL. Complications of Bacilltus Calmette-Gurin immunotherapy. Urol Clin North Am 1992;19:565-572.
 
19) 芝 政宏,藤井孝祐,高寺博史.BCG膀胱内注入療法後生じたライター症候群の1例.泌尿紀要2003;49:599-601.
 
20) 安永豊, ,原出泰規,三木恒治ら.膀胱癌に対するBCG注入療法と関節炎.リウマチ病セミナーVIII (七川歡次監修) , 1997,p 59-63 ,大阪,永井書店.
 
21) 嶺井定紀,入江 啓,陳 偉強ほか.BCG膀胱内注人療法後に発症した関節炎の検討.泌尿会誌2004;95:657-662.
 
22) 浅山 敬,佐野直樹,村越秀行ほか.膀胱癌に対するBacillus Calmette-Guerin(BCG) 療法後に生じた多発関節炎.日内会誌2004;93:1000-1002.
 
23) Orisaka K, Namima T, Ota S, et al. Acute eosinophilic pneumonia associated with intravesical bacillus Calmette-Guerin therapy of carcinomma in situ of the bladder. Int J Urol 2003;10:622-624.
 
24) Narvaez J, Castro-Bohorquez FJ, Vilaseca-Momplet J. Sjogrenis-like syndrolne following intravesical bacillus Calmette-Guerin immunotherapy. Am J Med 2003;115:4187-420.
 
25) Pardalidis NP, Papatsoris AG, Kosmaoglou EV, et al:Two cases of acute polyarthritis secondary to intravesica BCGadjuvant therapy for superficial bladder cancer. Clin Rheumatol 2002;21:536-537.
 
26) Clavel G, Grados F, Cayrolle G, et al. Polyarthritis following intravesical BCG immunotherapy:report of a case and review of 26 cases in the literature. Rev Rhum 1999;66:115-118.
PubMed
27) Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005;38:295-301.
PubMed
28) Geier DA, Geier MR. Hepatitis B vaccination and arthritic adverse reactions:a follow up analysis of the Vaccine Adverse Events Reporting System(VAERS) database. Clin Exp Rheumatol 2002;20:119.
 
29) Fisher MA, Eklund SA, James SA, et al. Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age,1993 and 1994. Ann Epidemiol 2001;11:13-21.
PubMed
30) Offit PA, Hackett CJ. Addressing parentsi concerns:Do vaccines cause allergic or autoimmune diseases? Pediatrics 2003;111:653-659.
PubMed
31) Dudos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2003;2:225-231.
 
32) Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005;23:3876-3886.
 
33) Kato T, Kiire A, Yamagata H, et al. Hypersensitivity reaction against influenza vaccine in a patient with rheumatoid arthritis after the initiation of etanercept injections. Mod Rheumatol 2006;16:327-329.
 
34) Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmune 1996;9:699-703.
PubMed
35) Marshall E. A shadow falls on Hepatitis B vaccination effort. Science 1998;281-630-631.
 
36) Dicklnan S, Possible cause found for lyme arthritis. Science 1998;281-631.
 
37) Trollmo C, Meyer AL, Steere AC, et al. Molecular mimicry in Lyme arthtitis demonstrated at the single cell level:LFA-1α Lis a partial agonist for outer surface protein A-reactive T cells. J Immunol 2001;166:5286-5291.
 
38) Belmatong E, Levy-Ojebbour, Appelboom T, et al. Polyarthritis in four patients treated with intravesical BCG for bladder carcinoma. Rev Rhum 1993;60:130-131.
 
39) Descotes J, Ravel G, Ruat C. Vaccines:predicting the risk of allergy and autoimmunity. Toxicology 2002;174:45-51.
PubMed
40) Silveira PA, Baxter AG. The NOD mouse as a model of SLE. Autoimmunity 2001;34:53-64.
 
41) Prescott S, James K, Busuttil A, et al. HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 1989;63:264-269.
PubMed
P.63 掲載の参考文献
1) 村田紀和.脊椎関節炎に対する生物学的製剤の効果.リウマチ病セミナーXVI(七川歡次監修) ,2005, p 214-221,大阪,永井書店.
 
2) Bennett RM. Psoriatic arthritis. In:McCarty DJ, editor. Arthritis and allied conditions,11th ed, Philadelphia London:Lea & Febiger;1989:954-971.
 
3) Blumberg BS, Bunim JJ, Calkins E, et al. ARA nomenclature and classification of arthritis and rheumatism (tentative) .Arthritis Rheum 1964;7:93-97.
PubMed
4) Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
 
5) 麻生和雄.炎症性角化症.現代の皮膚科学(三木吉治,笹井陽一郎,大河原章編集) ,1981,p 128-132,東京,金原出版.
 
6) Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan:nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001;28:554-559.
PubMed
7) 井上康二.慢性関節リウマチと変形性関節症,乾癬性関節炎の鑑別.Medicina 1998;35:1712-1713.
 
8) Avila R, Pugh DG, Slocum CH, et al. Psoriatic arthritis:a roentgenologic study. Radiology 1960;75:691-702.
 
9) 井上康二.乾癬性関節炎の脊椎病変.リウマチ科2005;34:567-572.
 
10) Bywaters EGL, Dixon St J. Paravertebral ossification in psoriatic arthritis. Ann Rheum Dis 1965;24:313-331.
 
11) Blau RH, Kaufman RL. Erosive and subluxing cervical spine disease in patients with psoriatic arthritis. J Rheumatol 1987;14:111-117.
PubMed
12) Bennett RM. Psoriatic arthritis. In:McCarty DJ, editor. Arthritis and allied conditions,9th ed, Philadelphia London:Lea & Febiger;1979:645.
 
13) Vasey F, Espinosa LR. Psoriatic arthropathy. In:Calin A, editor. Spondyloarthropathies. Orlando (FL) :Grune & Stratton;1984:151-185.
 
14) Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis:an analysis of 220 patients. Q J Med 1987;238:127-141.
PubMed
15) Amor B, Dougados M, Mijiyama M. Criteres de classification des spondylarthropathies. Rev Rhum 1990;57:85-89.
 
16) 辻本正記,谷 仁孝,喜多貞夫ほか.SpondylarthropathyにおけるAmorのClassification criteriaの検討.リウマチ病セミナーII(七川歡次監修) ,2001, p 25-31,大阪,永井書店.
 
17) Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-1227.
 
18) McGonagle D, Conagham PG, Emery P. Psoriatic arthritis:a unified concept twenty years on. Arthritis Rheum 1999;42:1080-1086.
 
19) Fournie B, Crognier L, Arnaud C, et al:. Proposed classification criteria of psoriatic arthritis:apreliminary study in 260 patients. Rev Rhum Engl Ed 1999;66:446-456.
 
20) Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis:development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-2673.
 

骨関節, 脊椎, 神経

P.69 掲載の参考文献
1) Piedmont RL. Does spirituality represent the sixed factor of personality? Spiritual transcedence and the five-factor model. J Personality 1999;67:985-1013.
 
2) 鈴木大拙.日本的霊性.1972, 東京,岩波書店.
 
3) 小田 晋,中島 宏,荻重田千鶴子ほか.「健康と霊性」,2001, 東京,宗教心理出版.
 
4) 日野原重明.いのちを創る.2002,東扉,講談社.
 
5) Salter WL. Measuring religion and spirituality:Where are we and where are we going? J Psychology & Theology 2001;29:4-21.
 
6) Ellison CW. Spiritual well-being:conceptionalization and measurement. J Psycology & Theology 1983;11:330-340.
 
7) Benson PL, Ponahue MJ, Erikson JA. The Faith Matuality Scale:The Faith Matuality Scale. Re search in the Social Scientific Study of Religion 1993;5:1-26.
 
8) Hall TW, Edwards KJ. The initial developement and facror analyis of the spiritual assessment inventory. J Pscycology & Theology 1999;24:233-246.
 
9) Bufford RK, Paloatizian RF, Ellison CW. Norms for the spiritual well-being scale. J Psychology & Theology 1991;19:56-70.
 
10) Hall TW, Edwards KJ. The initial developement and factor analyis of the spiritual assessment inventory. J Pscycology & Theology 1999;24:233-246.
 
11) 田崎美弥子,野地有子,中根允文.WHOのQOL.診断と治療1995;83:2183-2197.
 
12) 田崎美弥子,松田正巳,中根允文.スピリチュアリティに関する質的調査の試み-健康およびQOLの概念のからみの中で-:日本医事新報2001;4036:24-32.
 
13) Thomas PB, Griggs MJ. Spirituality in aging:spiritual need or spiritual journey? J Gerontological nursing 1995;15:5-10.
 
14) 明智龍男.がんとこころのケア.2003,東京,日本放送出版協会.
 
15) 佐藤武男.がんを語る.2002,大阪,医歯薬ジャナル社.
 
16) 田中ウルベイ京, 奈良雅弘.ストレスに負けない技術.2005,東京,日本実業出版社,
 
17) 坂野雄二.認知行動療法.1995,東京,日本評論社.
 
18) Potter ML, Zausniewski JA. Spirituality, resourcefullness, and arthritis impact on health perception of elders with rheumatoid arthritis. J Holistic Nursing 2000;18:311-335.
 
19) Bartlett SJ, Piemont R, Bilderback A, et al. Spirituality, well-being and quality of life in people with rheumatoid arthritis. Arhtritis rheum 2003;49:778-783.
 
20) Astin JA, Beckner W, Sokken K, et al. Psychological intervations for rheumatoid arthritis:A meta-analysis of randomized controlled trials. Arthritis Rheum 2002;47:291-302.
 
21) Hawley DJ. Psycho-educational interventions in the treatment of arthritis. Bailliere's Clinical Rheumatology 1995;9:803-823.
PubMed
22) Lunglgren S, Slenstroem CH. Muscle relaxation training and quality of life in rheumatoid arthritis. Scand J Rheumatol 1999;28:47-53.
 
23) Bell IR, Dsniel A, Lewis A, et al. Strength of vital force in classical homeopathy. Bio-Psycho-Social-Spritual correlates with a complexsystem context:J Alternative & Complementary Medicine 2004;10:123-131.
 
24) Vandecreck L, Paget S, Horton R, et al. Religious and nonreligious coping methods among persons with rheumatoid arthritis. Arhthritis Rheum 2004;51:49-55.
 
25) Matthews DA. Prayer and sprituality. Rheuma Dis Clin North Amer 2000;'26:177-187.
 
26) King M, Speck PT, Homas A. The effect of spiritual belief in outcome from illness. Social Science & Medicine 1999;48:1291-1299.
 
27) Nicassio PE, Schuman C, Kim J, et al. Psychosocial factors associated with complementary treatment use in fibromyalgia. J Rheumatol 1997;24:2008-2013.
 
28) Dedert EA, Studts JL, Weissbecker I, et al. Religiosity may help preserve the cortisol rhythm in women with stress-related illness. Int J Psychiatry in a Medicine 2004;34:61-77.
 
29) 越智隆弘.運動器機能回復と想い.2005,大阪,メヂカルレビュー社.
 
P.74 掲載の参考文献
1) 桐山啓丸,毛久未子, 土田学ほか.リウマチ患者と天気予測に関する考察.下呂病院年報1999;26:62-65.
 
2) 行山康.(気象病・季節病とその臨床) リウマチ性疾患.日本医師会雑誌1992;107:1995-1998.
 
3) Edstrom G, Lundun G, Wramner T Investigations into the effect of hot, dry microclimate on peripheral circulation, etc., in arthritic patients. Ann Rheum Dis 1948;7:76-82.
 
4) Hill DF. Climate and arthritis. In:Hollander JL, McCarty Jr.DT editors. Arthritis and allied condition, chapter 15,Lea and febiger,8th ed, Philadelphia;1972;256-263.
 
5) Kremers HM, Nicola R, Crowson CS, et al. Therapeutic strategies in rheumatoid arthritis over a 40-year period. J Rheumatol 2004;31:2366-2373.
 
6) Sato J, Aoyama O, Yamazaki M, et al. Artificially produced meteological changes aggravate pain in adjuvant-induced arthritic rats. Neurosci Lett 2004;354:46-49.
 
7) Patberg WR. Correlation of erythrocyte sedimentation rate and outdoor temperature in a patient with rheumatoid arthritis. J Rheumatol 1997;24:1017-1018.
 
8) Patberg WR, Raster JJ. Weather effect in rheumatoid arthritis:from controversy to consensus. A review. J Rheumatol 2004;31:1327-1334.
 
9) Gorin AA, Jodhua M, James N, et al. Rheumatoid arthritis patients show weather sensitivity in daily life, but the relationship in not significant. Pain 1999;81:173-177.
 
10) Sibley JY. Weather and arthritis symptoms. J Rheumatol 1985;12:707-710.
 
11) 東 威.気象と慢性関節リウマチ.からだの科学1983;114:48-51.
 
12) 滝沢健司,島井哲志,田中正敏.慢性関節リウマチと環境因子との関係-日本各地における訴え率の季節的変動について.公衆衛生1991;59:887-889.
 
13) 延永 正.リウマチ性疾患と気象・季節.からだの科学1985;123:75-80.
 
14) 中園 清,村瀬 章,遠山知香子ほか.RA患者の天候について-心理的側面について-.中部リウマチ 1997;28:119-120.
 
15) 行山 康.季節とリウマチ性疾患.日生気誌2004;40:285-292.
 
16) Guedji D, Wirnberger A. Effect of weather condition on rheumatic patient. Ann Rheum Dis 1990;49:158-159.
 
17) Stusberg I, Mendenberg RC, Serra HA, et al. Influence of weather condition on rheumatic pain. J Rheumatol 2002 ;29:335-338.
 
18) 西岡淳一.Fibromyalgiaのレゾンデトール.リウマチ病セミナーV(七川歡次監修) ,1994, p 69-77,大阪, 永井書店.
 
19) 赤真秀人.線維筋痛症,膠原病・リウマチ診察(東京女子医科大学付属膠原病リウマチ痛風センター編,鎌谷直之監修) ,2000,p 294-301 ,東京,メディカルビュー.
 
20) Fors EA, Sexson H. Weather and pain in fibromyalgia:are they related? Ann Rheum Dis 2002;61:247-250.
 
21) McLeogd J. Gout and Fibrositis in cold weather[letter].Med J Aust 1972;1:943.
PubMed
22) Arber N, Vaturi M, Schapiro JM, et al. Effect of weather condition on acute gouty arthritis. Scand J Rheumatol 1994;23:22-24.
PubMed
23) Schlesinger N, Gowin KM, Baker DG, et al. Acute gouty arthritis is seasonal. J Rheum 1998;25:342-344.
PubMed
24) Challier B, Urlacher F, Vancon G, et al. Is quality of life affected by season and weather condition in ankylosing spondylitis? Clin Exp Rheumatol 2001;19:279-281.
 
25) 竹内 勤.全身性エリテマトーデス,膠原病・リウマチは治る.2005,p 95-115,東京,文春新書.
 
26) 松山 毅.急性リウマチ熱,膠原病・リウマチ診察(東京女子医科大学付属膠原病リウマチ痛風センター編, 鎌谷直之監修) ,2000,p 270-278,東京,メディカルビュー.
 
27) 塩沢俊一..ベーチェット病,膠原病学 免疫学・リウマチ性疾患の理解のために,2003,p 422-432,東京,丸善株式会社.
 
28) 塩沢俊一'.強皮症,膠原病学 免疫学・リウマチ性疾患の理解のために,2003,p 350-363,東京,丸善株式会社.
 
29) 國谷 剛,塩田敬司.浜田一寿ほか:潜水病検診にみられた上腕骨頭壊死の長期観察例.関東整災誌1999; 31:5-11.
 
P.81 掲載の参考文献
1) Exar EN, Collop NA. The upper airway resistance syndrome. Chest 1999;115:1127-1139.
PubMed
2) Montserrat JM, Badia JR Upper airway resistance syndrome. Sleep Med Rev 1999;3:5-21.
PubMed
3) Phillipson EA, Bowes G. Sleep disorders. Update:Pulm Diseases and Disorders. New York:McGraw-Hill;1982:256-273.
 
4) Guilleminault C, Stoohs R, Clerk A, et al. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993;104:781-787.
 
5) Strollo PJ Jr, Rogers RM. Obstructive sleep apnea. N Engl J Med 1996;334:99-104.
PubMed
6) Bao G, Guilleminault C. Upper airway resistance syndrome-one decade later. Curr Opin Pulm Med 2004;10:461-467.
PubMed
7) Gold AR, Dipalo F, Gold MS, et al. The symptoms and signs of upper airway resistance syndrome:a link to the functional somatic syndromes Chest 2003;123:87-95.
 
8) Guilleminault C, Stoohs R, Kim YD, et al. Upper airway sleep-disordered breathing in women. Ann Intern Med 1995;122:493-501.
PubMed
9) 志水正敏.関節リウマチと閉塞性睡眠障害.リウマチ病セミナーXIV(七川歡次監修) , 2003, p 194-202, 永井書店,大阪.
 
10) Moldofsky H, Scarisbrick P, England R, et al. Musculoskeletal symptoms and non REM sleep disturbance in patients with"fibrositis"syndrome and healthy subjects. Psychosom Med 1975;37:341-351.
 
11) Moldofsky H. Sleep and fibrositis syndrome. Rheum Dis Clin North Am 1989;15:91-103.
PubMed
12) Gold AR, Dipalo F, Gold MS, et al. Inspiratory airflow dynamics during sleep in women with fibromyalgia.Sleep 2004;27:459-466.
PubMed
P.91 掲載の参考文献
1) Postel M, Kerboull M. Total prosthetic replacement in rapidly destructive arthrosis of the hip joint. Clin Orthop Relat Res 1970;72:138-144.
PubMed
2) Rosenberg ZS, Shankman S, Steiner GC, et al. Rapid destructive osteoarthritis:clinical, radiographic, and pathologic features. Radiology 1992;182:213-216.
PubMed
3) Bock GW, Garcia A, Weisman MH, et al. Rapidly destructive hip disease:clinical and imaging abnormalities.Radiology 1993;186:461-466.
PubMed
4) Khanna N, Domb BG, Moshirfar A, et al. Rapidly destructive osteoarthropathy of the hip. Am J Orthop 2004;33:243-247.
 
5) Dieppe PA, Doherty M, Macfarlane DG, et al. Apatite associated destructive arthritis. Br J rheum 1984;23:84-91.
 
6) Doherty M, Hott M, MacMillan P, et al. A reappraisal of "analgesic hip". Ann Rheum Dis 1986;45:272-276.
 
7) Mitrovic DR, Riera H. Synovial, articular cartilage and bone changes in rapidly destructive arthropathy (osteoarthritis) of the hip. Rheumatol lnt 1992;12:17-22.
 
8) Ryu KN, Kim EJ, Yoo MC, et al. Ischemic necrosis of the entire femoral head and rapidly destructive hip disease:potential causative relationship. Skeletal Radiol 1997;26:143-149.
PubMed
9) Bangil M, Soubbrier M, Dubost JJ, et al. Subchondral insufficiency fracture of the femoral head. Rev Rhum Engl Ed 1996;63:859-861.
 
10) Yamamoto T, Bullough PG. The role of subchondral insufficiency fracture in rapid deg. truction of the hip joint:a preliminary report. Arthritis Rheum 2000;43:2423-2427.
 
11) Boutry N, Paul C, Leroy X, et al. Rapidly destructive osteoarthritis of the hip:MR imaging findings. AJR 2002; 179:657-663.
PubMed
12) Sugano N, Ohzono K, Nishii T, et al. Early MRI findings of rapidly destructive coxopathy. Magn Reson Imaging 2001;19:47-50.
 
13) Watanabe W, Sato Kozo, Itoi E, et al. Posterior pelvic tilt in patients with decreased lumbar lordosis decreases acetabular femoral head covering. Orthopedics 2002;25:321-324.
PubMed
14) Berger CE, Kroner A, Stiegler H, et al. Elevated levels of serum type I collagen C-telopeptide in patients with rapidly destructive osteoarthritis of the hip. Int Orthop 2004;29:1-5.
PubMed
15) 小橋潤己,坂井孝司,大園健二ほか.急速破壊型股関節症と変形性股関節症における骨塩量の比較.Hip Joint 2005;31:282-284.
 
16) Komiya S, Inoue A, Sasaguri Y, et al. Rapidly destructive arthropathy of the hip. Studies on bone resorptive factors in joint fluid with a theory of pathogenesis. Clin Orthop Relat Res 1992;284:273-282.
 
17) Tamai M, Sagawa K, Kawabata R, et al. Production of IL-6 by T cells from the fernoral head of patients with rapidly destructive coxopathy(RDC) .Clin Exp Immunol 1996;103:506-513.
 
18) Masuhara K, Nakai T, Yamaguchi K, et al. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 inn patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 2002; 46:2625-2663.
 
19) Yamakawa T, Sudo A, Tanaka M, et al. Microvascular density of rapidly destructive arthropathy of the hip joint. J Orthop Surg 2005;13:40-45.
 
20) 小河賢司,北島 将,重松正森ほか.急速破壊型股関節症の骨頭所見から見た病型分類の試み. Hip Joint 2005 ;31:397-401.
 
21) 重松正森,佛淵孝夫.(高齢者の骨関節疾患) 関節疾患の治療と疼痛対策 股関節症.臨床と研究2005;82:955-961.
 
P.99 掲載の参考文献
1) 森山成彬.PTSDの歴史的展望と病態.臨床精神医学2000;29:5-10.
 
2) 飛鳥井望.外傷概念の歴史的変遷とPTSD.精神治療学1998;13:811-818.
 
3) 大塚俊弘,中根允文.精神科診断学体系におけるPTSD概念の位置づけ.外傷後ストレス障害.臨床精神医学講座 S6(中根允文,飛鳥井望編集) ,2000, p 3-17,東京, 中山書店.
 
4) 黒木宣夫.PTSDと補償.外傷後ストレス障害.臨床精神医学講座. S6(中根允文 飛鳥井望編集) , 2000. p 327-336,東京,中山書店,
 
5) 岡田幸之,安藤久美子,佐藤親次.司法精神医学とPTSD.臨床精神医学2000;29:118-123.
 
6) 山上 皓.犯罪被害者におけるPTSD.精神治療学1998;13:941-950.
 
7) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders,4(h ed(DSM-IV) . Washington DC;APA;1994.高橋:郎,花田耕一,藤縄昭 訳. DSM-IV精神疾患の診断.統計マニュア ル第1版,1996,p 435-436,東京,医学書院.
 
8) 金 吉晴.厚生労働省版「非常時地域精神保健医療ガイドライン」について,トラウマティック.ストレス 2004;2:201-217.
 
9) 小西聖子.犯罪被害者.臨床精神医学講座S 6(中根允文,飛鳥井望編集) ,2000, p 147-157 ,東京, 中山書店.
 
10) 飛鳥井望.PTSDの治療学.臨床精神医学増 増刊号2002:105-110.
 
11) Effective Treatments for PTSD. Practice Guidelines from the International Society for Traumatic Stress Studies. In:Foa EB, Keane TM, Friedman MJ, eds, New York:Guilford Press;2000.飛鳥井望,西園 文 石井朝子訳.PTSD治療ガイドライン,2005, p 84-103.金剛出版.
 
12) Davidson JRT. PTSD の有効な治療法.トラウマティック.ストレス2004;2:136155.
 
13) Foy DW, Schnurr PP, Foa EB. Cognitive-Behavioral Approaches to PTSD, Treating Psychological Trauma & PTSD. In Wilson JP, Friedman MJ, Lindy JD, eds, New York;Guilford Press;2004:159-182.
 
14)市井雅哉. EMDR.臨床精神医学講座S 6(中根允文,飛鳥井望編集) ,2000, p 274-282 東京,中山書店.
 
15) 山本英典ほか. PTSDの脳画像研究. PTSDの生物学的研究病態生理.臨床精神医学増刊号2002:50-58.
 
16) 本間研一.神経内分泌. PTSDの生物学的研究病態生理.臨床精神医学増刊号2002:67-71.
 
17) 森信 繁.生化学的研究.PTSDの生物学的研究病態生理.臨床精神医学増刊号2002:72-78.
 
P.111 掲載の参考文献
1) Sheon RP, Moskowitz RW, Goldberg W. Soft tissue rheumatic pain:recognition, management, and prevention.3rd ed.1996, Baltimore:Williams & Wilkins.
 
2) Wheeler AH. Myofascial pain disorders:theory to therapy. Drugs 2004;64:45-62.
PubMed
3) Facco E, Ceccherelli F Myofascial pain mimicking radicular syndromes. Acta Neurochir Suppl 2005;92:147-150.
PubMed
4) 財団法人厚生統計協会編.2006年「国民衛生の動向」:有訴者率,通院者率.厚生の指標.2006(臨時増刊) ;53:422-423.
 
5) 吉野良平.神経痛.リウマチと神経痛改訂増補版(七川歡次,吉野良平著) ,1972,p 131-236,大阪,藤沢薬品工業.
 
6) Travell JG, Simons DG. Myofascial pain and dysfuction. in 2 volumes,1992, Baltimore:Williams & Wilkins.
 
7) Chung JW, Ohrbach R, McCall WRJr. Effect of increased sympathetic activity on electrical activity from myofascial painful areas. Am J Phys Med Rehabil 2004;83:842-850.
 
8) Ariji Y, Sakuma S, Izumi M, et al. Ultrasonographic features of the masseter muscle in female patients with temporomandibular disorder associated with myofascial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:337-341.
PubMed
9) Edwards J. The importance of postural habits in perpetuating myofascial trigger point pain. Acupunct Med 2005;23:77-82.
PubMed
10) Hsin ST, Yin YC, Juan CH, et al. Myofascial pain syndrome induced by malpositioning during surgery-a case report. Acta Anaesthesiol Sin 2002;40:37-41.
PubMed
11) Cummings M. Myofascial pain from pectralis major following trans-axillary surgery. Acupunct Med 2003;21:105-107.
 
12) Levit K, Olsanska S. Clinical importance of active scars:abnormal scars as a cause of myofascial pain. J Manipulative Physiol Ther 2004;27:399-402.
 
13) Treaster D, Marras WS, Burr D, et al. Myofascial trigger point development from visual and postual stressors during computer work. J Electromyogr Kinesiol 2006;16:115-124.
 
14) 鈴木重行,平野幸伸,鈴木敏和.触診の基本事項. ID触診術第2版-Individual Muscle Palpation(鈴木重行編) ,2006,p1-2,東京,三輪書店.
 
15) 鈴木重行,平野幸伸,鈴木敏和.IDストレッチングのための基礎知識. IDストレッチング第2版-Individual Muscle Stretching(鈴木重行編) ,2006, p 14-16,東京,三輪書店.
 
16) 河上敬介,磯貝 香.各論の構成.骨格筋の形と触察法(河上敬介,小林邦彦編) ,2000,p 8-15,熊本,大峰閣.
 
17) 日本リウマチ学会編.線維筋痛症候群.リウマチ入門第11版[日本語版].1999,p 172-176,東京,萬有製薬株式会社.
 
18) Schneider MJ. Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome:aneed for clarity in terminology and differential diagnosis. J Manipulative Physiol Ther 1995;18:398-406.
 
19) Tunks E, McCain GA, Hart LE, et al. The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and control. J Rheumatol 1995;22:944-952.
PubMed
20) Borg-Stein J, Stein J. Trigger points and tender points:one and the same? Does injection treatment help? Rheum Dis Clin North Am 1996;22:305-322.
PubMed
21) de las Penas CF, Cuadrad ML, Gerwin RD, et al. Referred pain from the trochlear region in tension-type headache:amyofascial trigger point from the superior oblique muscle. Headache 2005;45:731-737.
 
22) Gavish A, Winocur E, Menashe S, et al. Experimental chewing in myofascial pain patients. J Orofac Pain 2002;16:22-28.
PubMed
23) Teachey WS. Otolaryngic myofascial pain syndromes. Curr Pain Headache Rep 2004;8:457-462.
PubMed
24) 西林保朗.職業とリウマチ病.リウマチ病セミナーVII(七川歡次監修) ,1996,p 112-128,大阪.永井書店.
 
25) 西林保朗.Piriformis Syndrome.リウマチ病セミナーII(七川歡次監修) ,1991, p 117-136,大阪,永井書店.
 
26) Doggweiler-Wiygul R. Urologic myofascial pain syndromes. Curr Pain Headachee Rep 2004 ;8:445-451.
PubMed
27) Jarrell J. Myofascial dysfunction in the pelvis. Curr Pain Headache Rep 2004;8:452-456.
PubMed
28) 西林保朗.リウマチ性疾患の四肢痛.リウマチ科2002;27(supple 1) :151-161.
 
29) 村田紀和.こむら返りとその治療.リウマチ病セミナーX(七川歡次監修) ,1999,p 91-96,大阪,永井書店.
 
30) Beebe FA, Barkin RL, Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther 2005;12:152-171.
 
31) Delaney JP, Leong KS, Watkins A, et al. The short-term effects of myofascial trigger point massage therapy on cardiac autonomic tone in healthy subjects. J Adv Nurs 2002;37:364-371.
PubMed
32) Gur A, Sarac AL, Cevik R, et al. Efficacy of 904nm gallium arsenide low level laser therapy in the management of chronic myofascial pain in the neck:adouble-blind and randomize-controlled trial. Laser Surg Med 2004;35:229-235.
 
33) Ilbuldu E, Cakmak A, Disci R, et al. Comparison of laser, dry needling, and placebo laser treatment in myofascial pain syndrome. Photomed Laser Surg 2004;22:306-311.
PubMed
34) Ceylan Y, Hizmetli S, Silig Y. The effects of infrared laser and medical treatment on pain and serotonin degradation products in patients with myofascial pairl syndrome. A controlled trial. Rheumatol Int 2004;24:260-263.
PubMed
35) Smania N, Corato E, Fiaschi A, et al. Repetitive magnetic stimulation A novel therapeutic approach for myofascial pain syndrome. J Neurol 2005;252:307-314.
PubMed
36) Hou CR, Tsai LC, Cheng KF, et al. Immediate effect of various physical therapeutic modalities on cervical myofascial pain and trigger-point sensitivity. Arch Phys Med Rehabil 2002;83:1406-1414.
PubMed
37) Edwards J, Knowles N. Superficial dry needling and active stretching in the treatment of myofascial pain-a randomized controlled trial. Acupunct Med 2003;21:80-86.
 
38) Goddard G, Karibe H, McNeill C, et al. Acupuncture and sham acupuncture reduce muscle pain in myofascial pain patient. J Orofac Pain 2002;16:71-76.
 
39) Itoh K, Katsumi Y, Kitakoji H. Trigger point acupuncture treatment of chronic low back pain in elderly patients a blinded RCS. Acupunct Med 2004;22:170-177.
 
40) Kamanli A, Kaya A, Ardicogulu O, et al. Comparison of lidocain injection, botulinum toxin injection, and dry needle to trigger points in myofascial pain syndrome. Rheumatol Int 2005;25:604-611.
 
41) Graboski CL, Gray SD, Burnham RS. Botulinum toxin A versus bupivacain trigger point injections for the treatment of myofascial pain syndrome:Arandomized double blind crossover study. Pain 2005;118:170-175.
 
42) Winocur F, Gavish A, Emodi-Periman A, et al. Hypnorelaxation as treatment for myofascial pain disorder:a comparative study. Oral Surg Oral Med Oral Pathl Oral Radiol Endodo 2002;93:429-434.
 
P.122 掲載の参考文献
1) Iwamoto J, Takeda T. Stress fractures in athletes:review of 196 cases. J Orthop Sci 2003;8:273-278.
 
2) Steinbruck K. Epidemiology of sports injuries.25-year-analysis of sports orthopedic-traumatologic ambulatory care. Sportverletz Sportschaden 1999;13:38-52.
PubMed
3) Chard MD, Lachmann SM. Racquet sports. Patterns of injury presenting to a sports injury clinic. Brit J Sports Med 1987;21:150-153.
 
4) Kuhne CA, Zettl RP, Nast-Kolb D. Verletzung-und Beschwerdehaufigkeit im Tennisleistungs-und reitensport. Sportverletz Sportschaden 2004;18:85-89.
 
5) Winge S, Jorgensen U, Lassen Nielsen A. Epidemiology of injuries in Danish championship tennis. Int J Sports Med 1989;10:368-371.
PubMed
6) Silva RT, Takahashi R, Berra B, et al. Medical assistance at the Brazilian juniors tennis circuit. A one-year prospective study. J Sci Med Sports 2003;6:14-18.
 
7) Hutchinson MR, Laprade RF, Burnett II QM, et al. Injury surveillance at the USTA Boys'Tennis Championships:a 6yr study. Med Sci Sports Exerc 1995;27:826-830.
 
8) Lo YPC, Hsu YCS, Chan KM. Epidemiology of shoulder impingement in upper arm sports events. Br J Sports Med 1990;24:173-177.
 
9) Brasseur JL, Lucidarme O, Tardieu M, et al. Ultrasonographic rotator-cuff changes in veteran tennis players:the effect of hand dominance and comparison with clinical findings. Eur Radiol 2004;14:857-864.
PubMed
10) Carroll R. Tennis elbow:incidence in local league players. Brit J Sports Med 1981;15:250-256.
 
11) Verhaar JAN. Tennis elbow. Anatomical, epidemiological and therapeutic aspects. International Orthopaedics 1994;18:263-267.
 
12) 西岡英次,吉田健治.上腕骨外上顆炎の超音波診断.日手会誌2003;20:554-559.
 
13) Savnik A, Jensen B, Norregaard J, et al. Magnetic resonance imaging in the evaluation of treatment response of lateral epicondylitis of the elbow. Eur Radiol 2004;14:964-969.
PubMed
14) Kitai E, Itay S, Ruder A, et al. An epidemiological study of lateral epicondylitis(tennis elbow) in amateur male players. Ann Chir Main 1986;5:113-121.
PubMed
15) Roetert EP, Brody H, Dillman CJ, et al. The biomechanics of tennis elbow. An integrated approach. Clin Sports Med 1995;14:47-57.
PubMed
16) Reid M, Elliott B. The one-and two-handed backhands in tennis. Sports Biomech 2002;1:47-68.
PubMed
17) Giangarra CE, Conroy B, Jobe FW, et al. Electrolnyographic and cinematographic analysis of elbow function in tennis players using single-and double-handed backhand strokes. Am J Sports Med 1993;21:394-399.
PubMed
18) Kelly JD, Lombardo SL, Pink M, et al. Electromyographic and cinematographic analysis of elbow function in tennis players with lateral epicondylitis. Am J Sports Med 1994;22:359-363.
 
19) Bollen SR, Robinson DG, Crichton KI, et al. Stress fractures of the ulna in tennis players using a double-handed backhand stroke. Am J Sports Med 1993;21:751-752.
 
20) Young CC, Raasch WG, Geiser C. Ulnar stress fracture of the nondominant arm in a tennis player using a two-handed backhand. Clin J Sports Med 1995;5:262-264.
 
21) Lundin O, Hellstrom M, Nilsson I, et al. Back pain and radiological changes in the thoraco-lumbar spine of athletes. A long-term follow-up. Scand J Med Sci Sports 2001;11:103-109.
PubMed
22) Saraux A, Guillodo Y, Devauchelle V, et al. Are tennis players at increased risk for low back pain and sciatica? Rev Rhum 1999;66:143-145.
PubMed
23) Feit EM, Berenter R. Lower extremity tennis injuries:prevalence, etiology and mechanism. J Am Podiat Med Assoc 1993;83:509-514.
PubMed
24) Harn T, Foldspang A. Prevalent knee pain and sport. Scand J Soc Med 1998;26:44-52.
 
P.129 掲載の参考文献
1) Takeuchi Y, Suzuki H, Ogura S, et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005;90:5523-5527.
 
2) Berndt TJ, Schiavi S, Kumar R."Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005;289:1170-1182.
 
3) Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000;67:54-68.
PubMed
4) White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets(ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001; 86:497-500.
PubMed
5) Bemdt T, Craig TA, Bowe AE, et al, Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003;112:785-794.
 
6) Carpenter TO, Ellis BK, Insogna KL, et al. Fibroblast growth factor 7:an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 2005;90:1012-1020.
PubMed
7) Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-498.
PubMed
8) ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF 23. Nat Genet 2000;26:345-348.
PubMed
9) Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF 23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001;98:6500-6505.
 
10) Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis.Kidney Int 2004;65:1943-1946.
PubMed
11) Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor(FGF) -23 in patients with primary hyperparathyroidism. Eur J Endocrinol 2004;151:55-60.
PubMed
12) Kobayashi K, Imanishi Y, Koshiyama H, et al. Expression of FGF 23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 2005;78:2295-2301.
PubMed
13) Rowe PS, Kumagai Y, Gutierrez G, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004;34:303-319.
PubMed
14) Gowen LC, Petersen DN, Mansolf AL, et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF 45) results in increased bone formation and bone mass. J Biol Chem 2003;278:1998-2007.
PubMed
15) Rowe PS, Matsumoto N,Jo OD, et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CAO 74 and pepstatin. Bone 2006;39:773-786.
 
16) Hayashibara T, Hiraga T, Yi B, et al. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res 2004;19:455-462.
 
17) Nagel DE, Khosla S, Sanyal A, et al. A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. J Cell Biochem 2004;93:1107-1114.
PubMed
18) Nampei A, Hashimoto J, Hayashida K, et al. Matrix extracellular phosphoglycoprotein(MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 2004;22:176-184.
 

評価

P.139 掲載の参考文献
1) 小松原良雄.新しいDMARDS.リウマチ病セミナーXI(七川歡次監修) ,2000, p 194-203,大阪,永井書店.
 
2) 大田 寛,.七川歡次,吉野良平ほか.慢性関節リウマチの死囚調査(250症例) .臨床リウマチ1989;2:255-265.
 
3) Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular,radiographic, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009-1019.
PubMed
4) Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis:a prospective study. Lancet 2002;359:1173-1177.
PubMed
5) Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370-1380.
 
6) 生島 香,上田孝文,久田原郁夫ほか.慢性関節リウマチ患者における悪性腫瘍発症のリスク.別冊整形外科1998;34:19-22.
 
7) 鈴木康夫,若林孝幸,ジャクソン加奈子.悪性腫瘍と催奇形性.リウマチ科2004;32:171-177.
 
8) 小松原良雄.X線よりみた関節リウマチ患者の関節再建術の必要性.リウマチ病セミナーXVI(七川歓次監 修) ,2003,p 203-214,大阪,永井書店.
 
9) 小松原良雄.RAの上肢機能再建のタイミング.リウマチ病セミナーXV(七川歡次監修) ,2004, p 229-244, 大阪,永井書店.
 

検査法

P.143 掲載の参考文献
1) Gonzalez AB, Darby S. Risk of cancer from diagnostic X-rays:estimates for the UK and 140ther countries. Lancet 2004;363:345-351.
 
2) 諸澄邦彦.新聞報道された放射線被ばく事例の分析,日本放射線技師会雑誌2004;51(621) :5-10.
 
3) ICRP. Pregnancy and Medical Radiation. Publication 84,0xford:Pergamon Press;1983.
 
4) 相模 司,医療被ばく対策委員会,社団法人日本放射線技師会.診療放射線技師が知っておくべき医療放射線防護について.日本放射線技師会雑誌2005;52:53-54.
 
5) 柏田陽子, 桑原 宏,笹川泰宏,ほか.社団法人日本放射線技師会「医療被ばく相談の基本的姿勢と手順について」.日本放射線技師会雑誌2005;52(629) :65-83.
 
6) 近藤宗平.「人体は放射線に弱くて強い」.ブルーパックス.「人は放射線になぜ弱いか」,1998,p 91-130,東京,講談社.
 
7) 相模 司,医療被ばく対策委員会,社団法人日本放射線技師会.診療放射線技師が知っておくべき医療放射線防護について.日本放射線技師会雑誌2005;52(629) :41-52.
 
8) 相模 司,医療被ばく対策委員会,社団法人日本放射線技師会.診療放射線技師が知っておくべき医療放射線防護について.日本放射線技師会雑誌2005;52:40.
 
9) 宮本義嗣,医療被ばく対策委員会,社団法人日本放射線技師会.Interventional Radiologyの患者被ばく低減のために.日本放射線技師会雑誌2005;52:53-57.
 
10) 石口恒男,亀井誠二,大野和子.X線透視を用いたIVRの被ばくの基礎知識. Jpn J Intervent Radiol 2005; 20:136-141.
 
11) 飯田泰治,堀井純清,茶畑光浩,ほか.血管造影検査における術者の被曝線量評価と放射線防護用具による被曝低減.日本放射線技術会雑誌2004;60:1713-1722.
 
P.153 掲載の参考文献
1) 七川歡次.強直性脊椎炎と付着部炎再訪.リウマチ病セミナーXIII (七川歡次監修) , 2002,pp 48-54,大阪, 永井書店.
 
2) 杉本英治.spondyloarthropathyの画像診断.リウマチ科2005;34:559-566.
 
3) McGonagle D, Marzo-Ortega H, Benjamin M, et al. Report on the Second international Enthesitis Workshop. Arthritis Rheum 2003;48:896-905.
PubMed
4) Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondylo-arthropathy at entheses and related sites. J Anat 2001;199:503-526.
 
5) Dougados M, van der Linden S, Juhlin R, et al.The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-1227.
 
6) 福田眞輔,三浪三千男,斉藤輝信ほか.血清反応陰性関節炎患者の日本AS研究会第2回アンケート調査報告.日関外誌1999;18:167-176.
 
7) 井上康二,西岡淳一,福田真輔ほか.慢性関節リウマチ患.者におけるアキレス腱付着部炎.中部整災誌 1988;31:1902-1904.
 
8) Bywaters EGL. Heel lesions of rheumatoid arthritis. Ann Rheum Dis 1954;13:42-51.
 
9) Marzo-Ortega H, McGonagle D, O'Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy:a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112-2117.
PubMed
10) Morrison WB, Carrino JA, Schweitzer ME, et al. Subtendinous bone marrow edema patterns on MR images of the ankle:association with symptoms and tendinopathy. Am J Roentgenol 2001;176:1149-1154.
 
11) Bollow M, Braun J, Hamm B, et al. Early sacroiliitis in patients with spondyloarthropathy:evaluation with dynamic gadolinium-enhanced MR imaging. Radiology 1995;194:529-536.
PubMed
12) Lehtinen A, Taavitsainen M, Leirisalo-Repo M. Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. Clin Exp Rheumatol 1994;12:143-148.
PubMed
13) Kamel M, Eid H. Mansour R. Ultrasound detection of heel enthesitis:a comparison with magnetic resonance imaging. J Rheumatol 2003;30:774-778.
PubMed
14) Genc H, Cakit BD, Ttlncbilek I, et al. Ultrasonographic evaluation of tendons and enthesal sites in rheumatoid arthritis:comparison with ankylosing spondylitis and healthy subjects. Clin Rheumatol 2005; 24:272-277.
PubMed
15) Balint PV, Kane D, Wilson H, et al. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002;61:905-910.
PubMed

生物学的反応

P.162 掲載の参考文献
1) Akira S, S Uematsu, O Takeuchi. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
 
2) Akira S. Toll receptor families:structure and function. Semin Immunol 2004;16:1-2.
PubMed
3) Kaisho T, S Akira. Pleiotropic function of Toll-like receptors. Microbes Infect 2004;6:1388-1394.
 
4) Schroder NW, RR Schumann. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005;5:156-164.
 
5) Uematsu S, S Akira. The role of Toll-like receptors in immune disorders. Expert Opin 214.
 
6) Kobayashi M, MN Kweon, H Kuwata, et al. Toll-like receptor-dependent production of IL-12p 40 causes chronic enterocolitis in myeloid cell-specific Stat 3-deficient mice. J Clin lnvest 2003;111:1297-1308.
 
7) Seibl R, T Birchler, S Loeliger, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003;162:1221-1227.
 
8) Kyburz D, J Rethage, R Seibl, et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003;48:642-650.
 
9) van der Heijden IM, B Wilbrink, I Tchetverikov, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000;43:593-598.
 
10) Iwahashi M, M Yamamura, T Aita, et al. Expression of Toll-like receptor 20n CD 16+blood Inonocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004;50:1457-1467.
 
P.167 掲載の参考文献
1) Trebino CE, Stock JL, Gibbons CP, et al. Impaired Inflammatory and pain responses In mice lacking an Inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003;100:9044-9049.
PubMed
2) Urade Y, Hayaishi O. Prostaglandin D synthase:structure and function. Vitam Horm 2000;58:89-120.
PubMed
3) Hirawa N, Uehara Y, Ikeda T, et al. Urinary prostaglandin D synthase (beta-trace) excretion Incrases In the early stage of diabetes mellitus 2001;87:321-327.
 
4) Eguchi Y, Eguchi N, Oda H, et al. Expression of lipocalin-type prostaglandin D synthase(β-trace) In human heart and Its accumulation In the coronary circulation of angina patients 1997;94:14689-14694.
 
P.173 掲載の参考文献
1) Felson DT, Couropmitree NN, Chaisson CE, et al. Evidence for a Mendelian gene in a segregation analysis of generalized radiographic osteoarthritis:the Framingham Study. Arthritis Rheum 41:1064-1071,1998.
 
2) Horikawa K, Kasai Y, Yamakawa T, et al. Prevalence of osteoarthritis, osteoporotic vertebral fractures, and spondylolisthesis among the elderly in a Japanese village, J Orthop Surg 14:9-12,2006.
 
3) Spector TD, MacGregor AJ. Risk factors for osteoarthritis:genetics. Osteoarthritis Cartilage 12:S 39-44,2004.
 
4) Spector TD, Cicuttini F, Baker J, et al. Genetic influences on osteoarthritis in women:a twin study. BMJ 312:940-943,1996.
PubMed
5) Lorenzo P, Aspberg A, Onneriord P, et al. Identification and characterization of asporin. a novel member of the leucine-rich repeat protein family closely related to decorin and biglycan. J Biol Chem 276:12201-12211,2001.
 
6) Henry SP, Takanosu M, Boyd TC, et al. Expression pattern and gene characterization of asporin. a newly discovered member of the leucine-rich repeat protein family. J Biol Chem 276:12212-12221,2001.
PubMed
7) Kizawa H, Kou I, Iida A, et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet 37:138-144,2005.
PubMed
8) Grimaud E, eymann D, Redini F. Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. Cytokine Growth Factor Rev 13:241-257,2002.
 
9) Mustafa Z, Dowling B, Chapman K, et al. Investigating the aspartic acid(D) repeat of asporin as a risk factor for osteoarthritis in a UK Caucasian population. Arthritis Rheum 52:3502-3506,2005.
 
P.179 掲載の参考文献
1) Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
PubMed
2) Ouchi N, Kihara S, Funahashi T, et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14:561-566.
PubMed
3) Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
PubMed
4) Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP 30. Nat Med 2002;8:731-737.
 
5) Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487-37491.
 
6) Kumada M, Kihara S, Sumitsuji M, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:8589.
 
7) Ohashi K, Ouchi N, Kihara S, et al. Adiponectin I 164T mutation is associated with the metabolic syndrome and coronary artery disease. J Arn Coll Cardiol 2004;43:1195-1200.
 
8) Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318-1323.
PubMed
9) Ogawa Y, Masuzaki H, Hosoda K, et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999;8:1822-1829.
 
10) Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat:Possible contributor to vascular disease in obesity. Nature Med 1996;2:800-802.
PubMed
11) Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
PubMed
12) Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
PubMed
13) Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-674.
PubMed
14) Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a critical role in the development of obesity-related insulin resistance. J Clin Inverst 2003;112:1821-1830.
 
15) Curat CA, Miranville A, Sengenes C, et al. From blood monocyte to adipose tissue-resident macrophages.Diabetse 2004;53:1285-1292.
 
16) Charriere G, Cousin B, Arnaud E, et al. Preadipocyte conversion to macrophage. J Biol Chem 2003;278:9850-9855.
PubMed
17) Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
PubMed
18) Ouchi N, Kihara S, Arita Y, et al, Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappab signaling through a CAMP-dependent pathway. Circulation 2000;102:1296-1301.
PubMed
19) Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens,negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96:1723-1732.
PubMed
20) Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-2049.
PubMed
21) Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004;279:1304-1309.
PubMed
22) Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e 27-31.
 
23) Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice.Circulation 2002;106:2767-2770.
PubMed
24) Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 2005;11:1096-1103.
PubMed

治療と副作用

P.188 掲載の参考文献
1) 服部政治.日本における慢性疼痛を保有する患者に関する大規模調査.ペインクリニック2004;25:1541-1551.
 
2) Breivik H. Collett B, Ventafridda V, et al. Survey of chronic pain in Europe:prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4) :287-333.
PubMed
3) 高橋三郎,大野 裕,染谷俊幸(訳) :DSM-IV-TR精神疾患の診断.統計マニュアル,2003, p 479-484,医学書院.
 
4) クリニカル.エビデンス日本語版2002-2003,p 309,799,849,856,978,2003,日経BP社.
 
5) 伊藤絵美.認知行動療法入門:認知療法.認知行動療法 面接の実際(伊藤絵美) 2006,p 1-7,東京,星和書店.
 
6) DeGood DE, Tait RC. Assessment of Pain Beliefs and Pain Coping. In:Handbook of Pain Assessment(Ed, Turk DC and Melzack R) ,New York:The Guilford Press;2001:320-345.
 
7) 久保千春,野添新一,外須美夫.慢性疼痛(西間三馨編) .心身症診断.治療ガイドライン2006.p 178-203, 東京,協和企画.
 
8) 有村達之,小宮山博朗,細井昌子.疼痛生活障害評価尺度の開発.行動療法研究1997;23:7-15.
 
9) Bradley LA, Young LD, Anderson KO, et al. Psychological approaches to the management of arthritis pain. Soc Sci Med 1984;19(12) :1353-1360.
 
10) Kraaimaat FW, Brons MR, Geenen R, et al. The effect of cognitive behavior therapy in patients with rheumatoid arthritis. Behav Res Ther 1995;33(5) :487-495.
PubMed
11) Strahl C, Kleinknecht RA , Dinnel DL. The role of pain anxiety, coping, and pain self-efficacy in rheumatoid arthritis patient functioning. Behav Res Ther 2000;38 (9) :863-873.
PubMed
12) Rhee SH. Parker JC. Smarr KL. et al. Stress management in rheumatoid arthritis:what is the underlying mechanism? Arthritis Care Res 2000;13(6) :435-442.
PubMed
13) 細井昌子,久保千春.慢性疼痛の心身医療と帯状回-from Bench to Bed-. Clinical Neuroscience 2005; 23 (11) :1276-1279.
 
14) 細井昌子.こころとからだ,その治療の実践.痛みのケアー慢性痛,がん性疼痛へのアプローチ,熊澤孝朗(監修・編集) ,第1版,2006,p 127-141,東京,照林社.
 
15) 小林 靖.霊長類における帯状回の機能解剖学.Clinical Neuroscience 2005;23(11) :1226-1230.
 
16) 永井道明,加藤 敏.島皮質と帯状回.Clinical Neuroscience 2005;23(11) :1231-1235.
 
P.199 掲載の参考文献
1) 海老原克彦,東 博彦.変形性股関節症.発症と白然経過.図説整形外科診断治療講座(宇田川英一編集) , 1990,p 2-9,東京,メジカルビュー社.
 
2) 上好昭孝.変形性股関節症の保存療法と適応-和医大式股関節用S-splintを中心に-.股関節研究セミナー 1987;5:3-19.
 
3) 稗田 寛,宮城成圭,後藤 琢ほか.変形性股関節症.整形外科MOOK 1979;7:12-23.
 
4) 上好昭孝.股関節疾患に対する装具療法の位置づけと有効性.関節外科2001;20:1551-1558.
 
5) Jordan HH. Ortopedic Appliances(second Ed) .Splints and braces for treatment of congenital dislocation of the hip, C.C.Thomas;1963,121-127.
 
6) Bombelli R. Osteoarthritis of the Hip, Berlin:Springer-Verlag;1996:20-21.
 
7) 二ノ宮節夫,中村利孝,谷口和彦ほか.長期間自然経過観察例にみる変形性股関節症の進展について.Hip Joint 1983;9:174-179.
 
8) Pawwels F Gesammelte Abhandlungen zur Funktionellen Anatomie des Bewegungs-apparatus, Berlin, Heidelberg, New York:Springer;1965:96-112.
 
9) 宮永 豊.股関節のバイオメカニクス.整形外科1994;45:727-732.
 
10) Hartz AJ, Fischer M, Bril G, et al. The association of obesity with joint and osteoarthritis in the HANES data. J Chronic Dis 1986;39(4) :311-319.
 
11) 紫藤徹郎.変形性股関節症のintraosseous phlebographyと骨内圧.整形外科MOOK 1979;7:48-64.
 
12) 上好昭孝.装具療法Sスプリント:股関節症-患者と医師のためのガイド-(村瀬鎮雄,廣橋賢次編) , 2003,p 57-68,東京,金原出版.
 
13) Salter RB, Simmonds DF, Malcolm BW, et al. The biological effect of continuous passive motion on the healing of full-thickness defects in articular cartilage. An experimental investigation in the rabbit. J Bone Joint Surg Am 1980;62(8) :1232-1251.
 
14) 上好昭孝.変形性股関節症の装具療法.整形外科治療のコツと落とし穴(山内裕雄,小野村敏信,小林晶 編) ,1997,p 16-17,東京,中山書店.
 
15) 端 賢次,大橋弘嗣,北村嘉雄ほか.股関節疾患に対する運動療法の位置づけと有効性.関節外科2000; 20:1536-1548.
 
16) 上好昭孝.変形性股関節症リハビリテーション実践マニュアル.装具療法.MB Med Reha 2001;11:1-7.
 
17) 山田冶基.変形性股関節症の病態と生化学.関節の外科,1998, p 11-22,東京,医学書院.
 
18) Goldin RH, McAdam L, Louie JS, et al. Clinical and radiological survey of the incidence of osteoarthritis among obese patients. Ann Rheum Dis 1976;35(4) :349-353.
PubMed
19) Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in women in the general population:the Chingford Study. J Rheumatol 1993;20(2) :331-335.
PubMed
20) 土方浩美.寛骨臼回転骨きり術.整形外科MOOK 1993;[増刊-2]:20-24
 
21) Chanley J. Low friction arthroplasty of the hip;Theory and practice. New York:Springer;1979.
 
P.215 掲載の参考文献
1) FitzGerald GA, COX-2 and beyond:approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890.
PubMed
2) 江口勝美.COX-2選択的阻害薬の現況とさらなる可能性.医薬ジャーナル2003;39:83-92.
 
3) Sano H, Hla T, Maier JA, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992;89:97-108.
PubMed
4) Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues:effects of interleukin-1β , phorbol ester, and corticosteroids. J CIin Invest 1994;93:1095-1101.
 
5) 佐野 統,柱本 照,山出亮詞ほか.シクロオキシゲナーゼ-2遺伝子発現抑制による滑膜細胞へのアポトーシス誘導とRA治療への応用. Osteoporosis Japan 1999;7:4652.
 
6) Kusunoki N, Yamazaki R, Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum 2002;46:3159-3167.
PubMed
7) Kojima F, Naraba H, Sasaki Y, et al. Prostaglandin E, is an enhancer for interleukin-1 ,9-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 2003;48:2819-2828.
 
8) Kohno M,Aikawa Y, Tsubouchi Y, et al. Inhibitory effect of T-614, n-(3-formylamino-4-oxo-6phenoxy-4H-chromen-7-yl) methanesulfonamide, on tumor necrosis factor α-induced cytokine production and NF-k B activation in cultured human synovial cells. J Rheumatol 2001;28:2591-2596
 
9) 川口浩.RA関節破壊の分子メカニズム.臨床リウマチ2003;15:175-178.
 
10) Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity:a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-7568.
PubMed
11) Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-648.
PubMed
12) Veys EM. Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. Eur J Rheumatol lnflamm 1994;14:23-27.
 
13) Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998;37:937-945.
 
14) 水島 裕,星 恵子,川合眞一.UHAC 62(メロキシカム) カプセルの慢性関節リウマチに対する臨床評価:ピロキシカムカプセルを対象とした第III相群間比較試験.基礎と臨床1997;31:1115-1166.
 
15) Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study:a randomized controlled trial. JAMA 2000;284:1247-1255.
PubMed
16) Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1933.
PubMed
17) Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors:what advantages do the newest offer? Drugs 2003;63:33-45.
PubMed
18) 宗園 聰.高齢者に対するNSAIDs治療の注意点. NSAIDsの使い方-コツと落とし穴(水島裕編) ,2006,pp 108-109,東京,中山書店.
 
19) 細野 治,田中廣壽.高齢関節リウマチ患者における鎮痛薬の使い方.NSAIDsの使い方-コツと落とし穴 (水島裕編) ,2006,pp 110-111,東京,中山書店.
 
20) 塩川優一,延永 正,斎藤輝信ほか.非ステロイド性抗炎症剤による上部消化管障害に関する疫学調査.リウマチ1991;31:96-111.
 
21) Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non steroidal anti-inflammatory drugs. N Engl J Med 1999;340:18881899.
 
22) Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325:624-627.
PubMed
23) Perini RF, Ma L, Wallace JL. Mucosal repair and COX-2 inhibition. Curr Pharm Des 2003;9:2207-2211.
PubMed
24) Simon AM, Manigrasso MB,O'Connor Jp. Cyclooxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-976.
PubMed
25) FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001;19:S31-36.
 
26) Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-2288.
PubMed
27) Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectaladenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
 
P.221 掲載の参考文献
1) Yamada T. Serum Amyloid A(SAA) :a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999;37:381-388.
 
2) Baba S, Masago SA, Takahashi T, et al. A novel allelic variant serum amyloid A SAA 1γ:Genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995;4:1083-1087.
 
3) 奥田恭章,山田俊幸,高杉 潔,ほか.慢性関節リウマチに合併した二次性アミロイドーシスにおけるSAA1, SAA2,アポリポ蛋白Eの遺伝多型と疾患感受性の検討.リウマチ1999;39:3-10.
 
4) Tiitinen S, Kaarela K, Helin H, et al. Amyloidosis:incidence and early risk factors in patients with rheumatoid arthritis. Scand J Rheumatol 1993;22:15&161.
 
5) Okuda Y, Takasugi K. Diagnostic and prognostic study of secondary amyloidosis complicating rheumatoid arthritis. Amyloid and Amyloidosis, New York:Parthenon Publishing Group;1998:426-428.
 
6) 奥田恭章,高杉 潔,小山 徹,ほか.慢性関節リウマチに合併した2次性アミロイドーシス124例の臨床的検討.-胃十二指腸生検による診断と予後を中心として-.リウマチ1994;34:939-946.
 
7) Gertz MA, Secondary systemic amyloidosis:response and survival in 64 patients. Medicine 1991;70:246-256.
PubMed
8) Browning MJ. Ten years'experience of an amyloid clinic-Aclinicopathological survey. Q J Med 1985;54:213-227.
 
9) 奥田恭章,高杉 潔.アミロイドーシス合併RAの早期診断と予後.リウマチ科1999;21:460-465.
 
10) Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-29.
PubMed
11) Elkayam O, Hawkins PN, Lachmann H, et al.Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with lnfliximab. Arthritis Rheum 2002;46:2571-2573.
 
12) Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis α therapy in fifteen patients with Mamyloidosis secondary to inflammatory arthritides. Arthritis Rheum 2003;48:2019-2024.
 
13) Hagihara K, Nishikawa T, Isobe T, et al.IL-6 plays a critical role in the synergistic induction of human amyloid A(SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative IU 7-PCR assay system. Biochem Biophys Res Commun 2004;314:363-369.
 
14) Okuda Y, Kiyoshi T. Successful use of a humanized anti-interleukin-6 receptor antibody, Tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthriris. Arthritis Rheum 2006;54:2997-3000.
 
15) Ravid M. Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis. Ann Rheum Dis 1982 ;41:587.
PubMed
16) Hazenberg BPC, et al. EULAR 2005-Annu Eur Cong Rheumatol(June 8-1, Vienna) ,2005.
 
P.232 掲載の参考文献
1) Bartlett RR, Schleyerbachi R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity-L Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985;7:7-18.
 
2) Bartlett RR, Mattar T, Weithamann U, et al. Leflunomide(HWA 486) :a novel immunorestoring drug. In Therapeutic Approches to Inflammatory Disease(A.J. Lewis, N.S.Doherty, N.R.Ackermann, eds) ,New York:NY Elsevier;1989:215-228.
 
3) Barlett RR, Anganostopulos H, Zielinski T, et al. Effect of leflunomide on immuno responses and models of inflammation. Springer Semin. Immunopathol 1993;14:381-394.
 
4) Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41(6) :421-430.
PubMed
5) Ullrichi A, Knecht W, Fries M, et al. Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects? Eur J Biochem 2001;268(6) :1861-1868.
 
6) Allison AC. Immunosuppressive drugs the first 50 years and a glance forward.2000;47:63-83.
 
7) Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000;47:247-257.
PubMed
8) Williamson RA, Yea CM, Robson PA, et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A 771726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270 (38) :22467-22472.
 
9) Cao WW, Kao PN, Chao AC, et al. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its anti-proliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant 1995;14:1016-1030.
PubMed
10) Urushibara M, Takayanagi H, Koga T, et al. The antirheumatic drug lefunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 2004;50(3) :794-804.
 
11) van Piel PL, Smolen JS, Emery P, et al. Leflunomide:a manageable safety profile. J Rheumatol Suppl 2004; 71:21-24.
 
12) Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159 (21) :2542-2550.
PubMed
13) 立石博臣,小川亮恵,中村孝志ほか.日本人RA患者におけるレフルノミド長期投与時の安全性および有効性の検討.新薬と臨床2003;7:932-958.
 
P.237 掲載の参考文献
1) Thatavatikom A, White AJ. Rituximab:a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2005;5 (1) :18-24.
 
2) Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25) :2572-2581.
PubMed
3) Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept;Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(8) :2263-2271.
PubMed

手術

P.245 掲載の参考文献
1) Fujiwara K, Yonenobu K, Ochi T. Natural history or upper cervical lesions in rheumatoid arthritis. J Spinal Disord 1997;10:275-281.
 
2) 細野 昇,米延策雄.画像診断 上位頸椎の臨床(冨永積生, 伊藤達雄,編) ,2000, pp 34-48,東京,南江堂.
 
3) Gallie WE. Fractures and dislocations of the cervical spine. Am J Surgery 1939;46:495-499.
 
4) McGraw RW, Rusch RM. Atlanto-axial arthrodesis. J Bone Joint Surg 1973;55-B:482-489.
 
5) Brooks AL, Jenkins EB. Atlanto-axial arthrodesis by the wedge compression method. J Bone Joint Surg 1978; 60-A:279-284.
 
6) Santavirta S, Konttinen, Laasonen E, et al. Ten-year results of operations for rheumatoid cervical spine disorderes. J Bone Joint Surg 1991;73-B:116-120.
 
7) Sumi M, Kataoka O, Ikeda M, et al. Atlantoaxial dislocation. A follow-up study of surgical results. Spine 1997; 22:759-764.
PubMed
8) Magerl F, Seemann PS. Stable posterior fusion of the atlas and axis by transarticular screw fixation. In:Kehr R Weidner A, editors. Cervical Spine l, Wien, New York:Springer-Verlag;1987:322-327.
 
9) Grob D, Jeanneret B, Aebi M, et al. Atlanto-axial fusion with transarticular screw fixation. J Bone Joint Surg Br 1991;73B:972-976.
 
10) 松本守雄,千葉一裕, 石井 賢ほか.RA環軸関節亜脱臼に対するMagerl法施行例の検討.臨整外2004; 39:1257-1262.
 
11) Neo M, Matsushita M, Iwashita Y, et al. Atlantoaxial transarticular screw fixation for a high-riding vertebral artery. Spine 2003;28:666-670.
PubMed
12) Wright NM, Posterior C2 Fixation using bilateral, crossing C 2 laminar screws:case series and technical note. J Spinal Disord Tech 2004;17:158-162.
 
13) 星地亜都司,中村耕三.ナビゲーションシステムを用いたRA頸椎の手術法.臨整外2004;39:1271-1276.
 
14) Neo M, Sakamoto T, Fujibayashi S, et al. A safe screw trajectory for atlantoaxial transarticular fixation achieved using an aiming device. Spine 2005;30:E 236-242.
 
15) 向井克容,藤井隆太朗,坂浦博伸ほか.術前の3D-CTデータより作製したカスタムメイドガイドによるMagerl法.日本脊椎脊髄病学会雑誌2006;17(1) :259.
 
16) 鐙 邦芳.RA中下位頸椎病変の病態と手術治療.臨整外2004;39:1263-1269.
 
17) 清水敬親,笛木敬介,登出尚史ほか.RAにおける頭蓋頸椎移行部垂直性不安定性の病態と外科的治療.臨整外2004;39:1291-1298.
 
18) Mukai Y, Hosono N, Sakaura H, et al. Laminoplasty for cervical myelopathy caused by subaxial lesions in rheumatoid arthritis. Yoshihiro J Neurosurg(Spine 1) 2004;100:712.
 

書評

最近チェックした商品履歴

Loading...